TacticScaleWhat Johnson & Johnson Does & How It Makes Money (JNJ)
Updated October 2026 · reflects Johnson & Johnson's latest reported financials
Diversified healthcare giant making prescription drugs and medical devices. J&J earns revenue by selling prescription drugs through wholesalers, distributors, hospitals, and healthcare professionals.
How Johnson & Johnson makes money
J&J earns revenue by selling prescription drugs through wholesalers, distributors, hospitals, and healthcare professionals. It also sells medical devices and surgical technologies to hospitals, clinics, physicians, and eye care professionals.
What Johnson & Johnson does
Johnson & Johnson, founded in 1886 and based in New Brunswick, New Jersey, is a global healthcare company organized into two segments: Innovative Medicine and MedTech. Innovative Medicine develops prescription drugs across oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism, sold through wholesalers, distributors, retailers, hospitals, and healthcare professionals. The MedTech segment covers surgery, orthopedics, cardiovascular, and vision. It includes joint reconstruction, trauma, spine, and sports medicine products; tools for open, laparoscopic, and robotic surgery such as stapling systems, energy devices, and wound closure; breast aesthetics and reconstruction; ACUVUE contact lenses; and TECNIS intraocular lenses for cataract and refractive procedures.
Products & services
- ACUVUE contact lenses
- TECNIS intraocular lenses
- Oncology and immunology prescription medicines
- Orthopedic joint reconstruction, trauma and spine products
- Surgical stapling, energy devices and wound closure
- Robotic and laparoscopic surgery technologies
What is Johnson & Johnson worth?
On an owner-earnings DCF, Johnson & Johnson's most-likely value is about $204 versus a recent price near $261 (22% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$106) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Jointown Pharmaceutical (600998.SS) · Joincare Pharmaceutical Group Industry (600380.SS) · Amgen (AMGN) · Pfizer (PFE)